Search Results
Your search for them matches 6128 pages
Showing 3451 - 3500Douglas R. Lowy, MD, and John T. Schiller, PhD, Receive 2017 Lasker Award
Two scientists at the National Cancer Institute (NCI) received the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize and was...
Talking About Physician Burnout: Practical Strategies for Starting the Conversation
Would you rather explain the benefits of three cycles of bleomycin, etoposide, and cisplatin to a hostile crowd of bored teenagers than talk to your program director, supervisor, or colleagues about feeling burned out? It is an understandable feeling. Professional burnout is a difficult concept to...
Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
On August 30, 2017, tisagenlecleucel (Kymriah) was granted regular approval for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.1,2 Tisagenlecleucel is the first chimeric antigen receptor (CAR)...
How Early Palliative Care May Benefit Patients With Incurable Cancer
Palliative care provided soon after a patient is diagnosed with incurable cancer not only helps improve the patient’s overall quality of life but also improves communication about the patient’s wishes for end-of-life care, according to a study by Jennifer S. Temel, MD, Clinical Director of Thoracic ...
Duration Studies in Oncology Have Often Been Poorly Designed and Analyzed
The ASCO Post is pleased to introduce “At Microphone 1,” an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings, and often at the microphone where he stands ready with important questions for...
News From JCO and JOP
STAYING UP-TO-DATE in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology (JCO) and the Journal of Oncology Practice (JOP). Future installments...
Sarcoma Management Is Slowly Evolving
THE BACKBONE treatment for soft-tissue sarcomas has long been anthracycline-based, but new approaches are coming. These novel strategies were discussed at the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, by Melinda L. Yushak, MD, MPH, Assistant Professor ...
Small Steps Forward in Brain Tumor Therapy
SOME RECENT ADVANCES in the treatment of brain tumors are promising, but others are less so, according to Jeffrey J. Olson, MD, Professor of Neurosurgery at Emory University, Atlanta. At the 2017 Debates and Didactics in Hematology and Oncology Conference, held in Sea Island, Georgia, and...
Is Complete Lymphadenectomy Still Standard of Care in Melanoma?
DOES COMPLETE lymph node dissection for sentinel node–positive melanoma still have a role in the management of this disease? That’s debatable. Although it does not improve overall survival over observation alone, complete lymphadenectomy may have other benefits, according to a dialogue at the...
PD-L1 Inhibitor Consolidation Therapy for NSCLC: New Standard of Care?
THE PROGRAMMED CELL DEATH ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) improved progression-free survival by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) whose disease did not progress following standard treatment ...
Hepatocellular Carcinoma: Current Thoughts on Liver Transplantation
LIVER TRANSPLANT offers the highest rates of long-term survival for patients with hepatocellular carcinoma, according to Maria Russell, MD, Assistant Professor of Surgery at Emory University, Atlanta. At the 2017 Debates and Didactics in Hematology and Oncology Conference at Sea Island, Georgia,...
Religiously Tailored Educational Intervention to Encourage Mammography in American Muslim Women
Despite the U.S. Preventive Services Task Force recommendation that women between the ages of 50 and 74 undergo mammography every 2 years, only about 50% of American Muslim women do so, compared with 67% of all American women. A study by Padela et al investigating the mammography-related barrier...
Positive Results from Phase III MURANO Trial Evaluating Venetoclax in Combination With Rituximab in Relapsed/Refractory CLL
The phase III MURANO study of venetoclax (Venclexta) tablets in combination with rituximab (Rituxan) met its primary endpoint. Results showed that the combination prolonged progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with bendamustine...
Combination of Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Relapsed or Refractory Ph-Negative ALL
In a single-center phase II trial reported in JAMA Oncology, Jabbour et al found that the combination of inotuzumab ozogamicin (Besponsa) and low-intensity chemotherapy produced promising results in patients with relapsed or refractory Philadelphia chromosome (Ph)-negative acute lymphoblastic...
Assessing and Managing CAR T-Cell Treatment Toxicities
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists—one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for...
New ASCO Guideline Aims to Improve Clinician Communication With Patients
A new guideline from ASCO published by Gilligan et al in the Journal of Clinical Oncology outlines best practices for cancer clinicians when communicating with patients and their loved ones. The Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline...
ESMO 2017: 'Triggers': A New Tool to Assess Patients’ Palliative Needs
A new tool to identify patients who would benefit from early palliative care was presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA54_PR). The so-called “Triggers” tool, developed by the London Cancer Alliance to help clinicians in the...
ESMO 2017: Patients Struggle With Key Aspects of Clinical Trial Methodology
Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at 3%–5%. A nationwide study in Ireland, the preliminary results of which were presented at the European Society for Medical Oncology...
FDA Approves Copanlisib for Adults With Relapsed Follicular Lymphoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to copanlisib (Aliqopa) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often...
ESMO 2017: Patients May Feel Psychosocial Impact of Chemotherapy More Acutely Than Physical Side Effects
The preliminary results of a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show that sociopsychological factors have become more significant for patients today than physical side effects such as nausea and vomiting, which were among the top concerns in...
Survey on Training in Geriatrics/Geriatric Oncology for Hematology-Oncology Fellows
Results from an ASCO-sponsored survey study indicate that despite professed interest in the area, most hematology-oncology fellows have inadequate training in geriatrics/geriatric oncology. These findings were reported in the Journal of Oncology Practice by Maggiore et al. Study Details The...
ESMO 2017: Adding Taselisib to Neoadjuvant Letrozole Improves Outcomes in Early Breast Cancer
Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor–positive and HER2-negative, according to results of the LORELEI trial, presented at the European Society for Medical Oncology (ESMO) 2017 Congress ...
ESMO 2017: DNA Sequencing Could Open Up New Drug Indications for Patients With Rare Cancers
Due to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers but who carry the same genetic mutations. The first results of a multidrug and multitumor clinical trial (Abstract...
Alzheimer’s Disease Risk in Medicare Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
As reported by Baik et al in the Journal of Clinical Oncology, Medicare patients who received androgen-deprivation therapy for prostate cancer do not appear to be at increased risk for Alzheimer’s disease and may have an extremely small increased risk for dementia. Study Details The study...
ESMO 2017: ALEX and ALUR Trials: Alectinib Shows CNS Benefit in ALK-Positive NSCLC
Data from two separate phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show the particular central nervous system (CNS) activity of alectinib (Alecensa) in patients with advanced non–small cell lung cancer involving a mutation of the...
Douglas R. Lowy, MD, and John T. Schiller, PhD, to Receive 2017 Lasker Award
Two scientists at the National Cancer Institute (NCI) will receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize,...
Zika Virus Shows Oncolytic Activity Against Glioblastoma Stem Cells in Preclinical Trial
Although Zika virus causes devastating damage to the brains of developing fetuses, it someday may prove to be an effective treatment for glioblastoma. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine showed that...
‘Substantial Improvements’ in the Treatment of Glioblastoma
NEWS ARTICLES about Senator John McCain’s diagnosis of glioblastoma accurately describe glioblastoma as aggressive and having a poor prognosis. But as Walter J. Curran, Jr, MD, pointed out in one of those reports, “substantial improvements in surgical approaches” have enabled more patients to...
Control
Many Type A personalities deal with problems by controlling all aspects of the problem. Sometimes this works. Sometimes it works for a while. Sometimes it doesn’t work at all. The health-care system—hospitals, clinics, and doctors’ offices—have policies (specific office hours and strict...
Cancer Has Robbed Me of a Life I Loved
I always knew cancer was a real possibility for me. Both my mother and father died of the disease—my mother of lung cancer and my father of bone cancer—so when I started having chronic throat and chest infections, I was diligent about seeking immediate medical attention and felt relieved each time ...
To the Last Drop
It was 2:15 PM, and my afternoon clinic had not yet begun. The morning had been particularly trying as a result of disastrous clinical developments for two of my long-standing patients. Jessica had metastatic breast cancer, and I had been taking care of her for 7 years. Multiple lines of...
Addressing the Challenges of Intimacy After Cancer
The literature has documented the stress and damage that intimacy problems cause among women undergoing cancer treatment and during survivorship. A new book, Sex and Cancer: Intimacy, Romance, and Love After Diagnosis and Treatment, by Saketh R. Guntupalli, MD, and Maryann Karinch tackles the...
Tales From the OR: A Pediatric Surgeon’s Memoir
CARING FOR sick children brings with it a set of emotional and physical challeneges that differ from those with the adult patient population. In a new book, Healing Children: A Surgeon’s Stories From the Frontiers of Pediatric Medicine, Kurt Newman, MD, draws on more than 30 years of his...
The Rising Incidence of Thyroid Cancer Reconsidered
Despite a significant rise in the incidence of thyroid cancer, the U.S. Preventive Services Task Force (USPSTF), a panel of independent experts in primary care and screening, has given thyroid cancer screening a D recommendation, which is a recommendation against screening. To shed light on this...
Get to Know Your ASCO President-Elect: Monica M. Bertagnolli, MD, FASCO
Monica M. Bertagnolli, MD, FASCO, a long-time member and volunteer, began her term as ASCO President-Elect in June 2017; she will serve as 2018–2019 ASCO President. An active ASCO member since 1995, Dr. Bertagnolli is Chief of the Division of Surgical Oncology at Dana-Farber/Brigham and Women’s...
Bridging the Survivorship Care Gap for Young Adult Survivors of Thyroid Cancer
Although thyroid cancer is among the five most common carcinomas diagnosed in adolescents and young adults (AYAs) between the ages of 15 and 39—thyroid cancer is more common in young women than young men and is the most common cancer diagnosed in females between the ages of 15 and 29 and the second ...
Shaping Real Careers With Virtual Mentorship
Institution: Postgraduate trainee and PhD candidate in medical oncology, Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of MedicineMember since: 2014ASCO activities: Virtual Mentors, Journal of Global Oncology editorial fellow Of the many activities ASCO...
Initiating the Topic of Weight and Health With Patients With Obesity
Rates of obesity have been steadily rising over the past 3 decades in both adults and children. Today, more than one-third of American adults and about 17% of children and adolescents, ages 6 to 19, have obesity.1 Cancer rates have risen in tandem with obesity rates, making obesity the second...
Testing Alpha-Emitting Radiolabeled Immunotherapy to Treat—and Potentially Cure—Multiple Myeloma
Despite a flurry of treatment advances in multiple myeloma over the past decade that have increased overall survival from just 2 to 3 years in the 1990s to between 5 and 7 years today—with some data suggesting an extended life expectancy of between 7 and 10 years1—the cancer remains stubbornly...
Award for Early Career Scientists in New York: Applications Open October 2, 2017
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will open for applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000/year—for up to 3 years—to enable them to pursue...
Multiple Myeloma: Researchers Are Digging Deeper Than Ever
Researchers are tackling multiple myeloma from many angles, and the result could be a flood of novel approaches soon within the oncologist’s reach, according to Kenneth C. Anderson, MD. At the 2017 Debates and Didactics in Hematology and Oncology Conference at Sea Island, Georgia, Dr. Anderson...
For the Impoverished, Health Care Is a Luxury
Cancer is the second leading cause of death worldwide, and the global burden is on an inexorably upward trajectory. For the year 2012, there were 14.1 million new cancer cases and 8.2 million cancer-related deaths worldwide.1 It is predicted that by the year 2035, there will be 23.9 million new...
Long-Term Follow-up of PIVOT Argues for Immediate Treatment of Men With Unfavorable-Risk and Possibly High-Volume, Low-Risk Prostate Cancer
The updated results of the PIVOT1 study—reported in The New England Journal of Medicine by Wilt et al and reviewed in this issue of The ASCO Post—did not show a statistically significant difference between treatment and observation for the initial management approach to men with newly diagnosed...
On My Way to Hospice Care, Immunotherapy Saved My Life
Two years ago, I was on my way to hospice care after numerous treatments, including surgery, chemotherapy, and radiation therapy failed to stop the progression of my stage IV castration-resistant prostate cancer. A last-minute call from my oncologist about a phase I trial of combination...
FDA Statement Regarding Safety Concerns Related to Investigational Use of Pembrolizumab in Multiple Myeloma
On August 31, U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research Director Janet Woodcock, MD, issued the following statement: “Clinical trials play a critically important role in bringing to market innovative new therapies for patients facing life-threatening...
Androgen-Deprivation Therapy May Be Associated With Higher Risk of Heart Failure in Early-Stage Prostate Cancer
Men with localized prostate cancer who received androgen-deprivation therapy were at significantly higher risk of heart failure than men who did not receive this therapy, according to a Kaiser Permanente study published by Haque et al in the British Journal of Cancer. In the past,...
Artificial Intelligence May Help With Earlier Detection of Skin Cancer
New technology being developed by researchers at the University of Waterloo and the Sunnybrook Research Institute is using artificial intelligence (AI) to help detect melanoma at earlier stages. The technology employs machine-learning software to analyze images of skin lesions and provide...
2018 Pershing Square Sohn Cancer Research Prize Opens for Applications on October 2, 2017
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will begin accepting applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000 per year—for up...
HPV Vaccination Rates Especially Low Among Childhood Cancer Survivors
The rate of human papillomavirus (HPV) vaccination in the United States is increasing, but remains lower than ideal. A new study suggests that survivors of childhood cancer receive the HPV vaccine at an even lower rate than their peers without cancer—24% vs 40%, respectively. Nearly...
Palliative Care May Substantially Decrease Health-Care Utilization in Patients With Advanced Cancer
A new population-based study shows that palliative care substantially decreased health-care utilization among Medicare beneficiaries with advanced cancer, resulting in less intensive care being delivered at the end of life. This included lower rates of hospitalization, fewer invasive procedures,...
